Topoisomerases I: New targets for cancer chemotherapy and mechanisms of resistance;Les topo-isomerases I: Nouvelles cibles pour le traitement des cancers et mecanismes de resistance

Bulletin du Cancer

Volumn 85, Issue SPEC. ISS. DEC., 1998, Pages 5-10

  Pourquier, Philippe ^a   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Camptothecins; Resistance; Topoisomerases

Indexed keywords

5,6 DIHYDRO 2,3 DIMETHOXY 6 METHYL 8,9 METHYLENEDIOXY 5,11 DIOXO 11H INDENO[1,2 C]ISOQUINOLINE; 6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A][PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; ANTHRACYCLINE DERIVATIVE; BENZ[A]ANTHRACENE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; CAMPTOTHECIN DERIVATIVE; CARBAZOLE DERIVATIVE; DACTINOMYCIN; DISTAMYCIN A; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; HOE 33342; ICRF 505; INTOPLICINE; KT 6006; NITIDINE; QUINOLINE DERIVATIVE; REBECCAMYCIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DNA; DRUG DERIVATIVE; ENZYME INHIBITOR; INTERCALATING AGENT; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CANCER RESISTANCE; DRUG EFFICACY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; REVIEW; BINDING SITE; BIOSYNTHESIS; CHEMISTRY; DNA REPLICATION; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; MACROMOLECULE; NEOPLASM; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; BINDING SITES; CAMPTOTHECIN; DNA REPLICATION; DNA TOPOISOMERASES, TYPE I; DNA, NEOPLASM; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; INTERCALATING AGENTS; MACROMOLECULAR SUBSTANCES; NEOPLASM PROTEINS; NEOPLASMS;

EID: 0032240899     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Wang JC. DNA topoisomerases. Annu Rev Biochem 1996 ; 65 : 635-92.
2. Champoux JJ, Dulbecco R. An activity from mammalian cells that untwists superhelical DNA - a possible swivel for DNA replication (polyoma-ethidium bromide-mouse-embryon cells-dye binding assay). Proc Natl Acad Sci USA 1972 ; 69 : 143-6.
3. Gupta M, Fujimori A, Pommier Y. Eukaryotic DNA topoisomerases I. Biochim Biophys Acta 1995 ; 1262 : 1-14.
4. Morham SG, Kluckman KD, Voulomanos N, Smithies O. Targeted disruption of the mouse topoisomerase I gene by camptothecin selection. Mol Cell Biol 1996 ; 16 : 6804-9.
5. Lee MP, Brown SD, Hsieh TS. DNA topoisomerase I is essential in Drosophila melanogaster. Proc Natl Acad Sci USA 1993 ; 90 : 6656-60.
6. Shykind BM, Kim J, Stewart L, Champoux JJ, Sharp PA. Topoisomerase I enhances TFIID-TFIIA complex assembly during activation of transcription. Gene Dev 1997 ; 11 : 397-407.
7. Wang HP, Rogler CE. Topoisomerase I-mediated integration of hepadnavirus DNA in vitro. J Virol 1991 ; 65 : 2381-92.
8. Bullock P, Champoux JJ, Botchan M. Association of crossover points with topoisomerase I cleavage sites : a model for nonhomologous recombination. Science 1985 ; 230 : 954-8.
9. Rossi F, Labourier E, Forne T, Divita G, Derancourt J, Riou JF, et al. Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature 1996 ; 381 : 80-2.
10. Gobert C, Bracco L, Rossi F, Olivier M, Tazi J, Lavelle F, et al. Modulation of DNA topoisomerase I activity by p53. Biochemistry 1996 ; 35 : 5778-86.
11. Shuman S. Site-specific DNA cleavage by Vaccinia virus DNA topoisomerase I. Role of nucleotide sequence and DNA secondary structure. J Biol Chem 1991 ; 266 : 1796-803.
12. Champoux JJ. Mechanistic aspects of type-I topoisomerases. In: Wang JC, Cozarelli NR. DNA topology and its biological effects. Cold Spring Harbor : Cold Spring Harbor Laboratory, 1990 ; 217-42.
13. Pourquier P, Pilon AA, Kohlhagen G, Mazumder A, Sharma A, Pommier Y. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. J Biol Chem 1997 ; 272 : 26441-7.
14. Pourquier P, Ueng LM, Kohlhagen G, Mazumder A, Gupta M, Kohn KW, et al. Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. J Biol Chem 1997 ; 272 : 7792-6.
15. Stewart L, Redinbo MR, Qiu X, Hol WGJ, Champoux JJ. A model for the mechanism of human topoisomerase I. Science 1998 ; 279 : 1534-41.
16. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WGJ. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science 1998 ; 279 : 1504-13.
17. Shuman S. Novel approach to molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase. J Biol Chem 1994 ; 269 : 32678-84.
18. Pommier Y, Pourquier P, Fan Y, Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1998 ; 1400 : 83-106.
19. Wall ME, Wani MC, Cooke CE, Palmer KH, McPhail AT, Slim GA. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 1966 ; 88 : 3888-90.
20. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985 ; 260 : 14873-8.
21. Svejstrup JQ, Christiansen K, Gromova II, Andersen AH, Westergaard O. New technique for uncoupling the cleavage and religation reactions of eukaryotic topoisomerase I. The mode of action of camptothecin as a specific recognition site. J Mol Biol 1991 ; 222 : 669-78.
22. Thomsen B, Mollerup S, Bonven BJ, Frank R, Blocker H, Nielsen OF, et al. Sequence specificity of DNA topoisomerase I in the presence and absence of camptothecin. EMBO J 1987 ; 6 : 1817-23.
23. Porter SE, Champoux JJ. Mapping in vivo topoisomerase I sites on simian virus 40 DNA : asymmetric distribution of sites on replicating molecules. Mol Cell Biol 1989 ; 9 : 541-50.
24. Jaxel C, Capranico G, Wassermann K, Kerrigan D, Kohn KW, Pommier Y. DNA sequence at sites of topoisomerase I cleavage induced by camptothecin in SV40 DNA. In : Potmesil M, Kohn KW. DNA topoisomerases in cancer. New York, Oxford : Oxford University Press, 1991 : 182-95.
25. Pommier Y, Kohlhagen G, Kohn F, Leteurtre F, Wani MC, Wall ME. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc Natl Acad Sci USA 1995 ; 92 : 8861-5.
26. Pommier Y, Leteurtre F, Fesen M, Fujimori A, Bertrand R, Solary E, et al. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest 1994 ; 12 : 530-42.
27. Hsiang YH, Lihou MG, Liu LF. Arrest of DNA replication by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989 ; 49 : 5077-82.
28. Holm C, Covey JM, Kerrigan D, Pommier Y. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells. Cancer Res 1989 ; 49 : 6365-8.
29. Hoki Y, Fujimori A, Pommier Y. Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Cancer Chemother Pharmacol 1997 ; 40 : 433-8.